Login/Sign Up
MRP ₹23663
(Inclusive of all Taxes)
₹2839.6 Cashback (12%)
Online payment accepted
Provide Delivery Location
Whats That
Therapeutic Class
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Kyprolis 30 mg Injection contains Carfilzomib, which inhibits proteasomes and thereby prevents protein breakdown in MM (multiple myeloma) cells. When the proteasome action within the MM cell is disturbed, a protein accumulation occurs, destroying the cancerous cells.
No, it is unsafe to father a child while taking Kyprolis 30 mg Injection. It is recommended for sexually active men to use condoms while on treatment and for at least several months after their last dose of Kyprolis 30 mg Injection.
Based on the medical condition, Kyprolis 30 mg Injection may be given alone or together with other medicines used to treat multiple myeloma.
Tell your healthcare professional immediately if you get any signs of an infusion-related reaction during or after the infusion. Your doctor may give other medicines, or the infusion may need to be slowed down or stopped.
Kyprolis 30 mg Injection can cause a significant decrease in the number of blood cells and platelets. Your doctor may suggest laboratory tests before and during the treatment. Tell your healthcare provider if you develop a fever or have signs of bruising or bleeding.
Alcohol
Caution
Avoid alcohol consumption while on treatment with Kyprolis 30 mg Injection.
Pregnancy
Unsafe
Kyprolis 30 mg Injection should not be taken during pregnancy as it might cause fetal harm. Inform your doctor immediately if you are conceiving while on therapy.
Breast Feeding
Unsafe
Do not breastfeed while you are receiving Kyprolis 30 mg Injection and for two weeks after your final dose.
Driving
Caution
Kyprolis 30 mg Injection may cause fatigue, dizziness, fainting, and/or a drop in blood pressure. So, if you have any of these symptoms while in therapy, you should not operate machinery or drive a car.
Liver
Caution
Extreme caution is exercised while using Kyprolis 30 mg Injection in patients with liver impairment. Inform your doctor if you have liver impairment. Your doctor monitors liver enzymes and withholds dosing if suspected.
Kidney
Caution
Limited information is available. Please inform your doctor before prescribing Kyprolis 30 mg Injection if you have kidney impairment. Your doctor will weigh the benefits and potential risks before prescribing Kyprolis 30 mg Injection.
Children
Caution
The safety and effectiveness of Kyprolis 30 mg Injection in pediatric patients have not been established.
Product Substitutes
Keep Refrigerated. Do not freeze.
About Kyprolis 30 mg Injection
Kyprolis 30 mg Injection belongs to the group of proteasome inhibitors (anti-cancer medicines). It is used alone and in combination with other medications to treat people with multiple myeloma (a type of cancer of the bone marrow) who have already been treated with other medicines. Multiple myeloma, also known as myeloma, is a type of bone marrow cancer that affects several areas of the body, such as the spine, skull, pelvis, and ribs.
Kyprolis 30 mg Injection contains Carfilzomib, which suppresses proteasomes that prevent protein breakdown in MM (multiple myeloma) cells. When proteasome function is stopped within the MM cell, a protein build-up occurs within the MM cell, which destroys the malignant cells.
Kyprolis 30 mg Injection is administered in a hospital setting by a physician qualified by training and experience to administer cancer chemotherapeutic agents. Sometimes, you may experience common side effects, such as fatigue (feeling overtired), anaemia, nausea, thrombocytopenia (low platelet level), dyspnea (feeling short of breath), diarrhoea, and pyrexia (fever). Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if any of these side effects persist or worsen.
Before taking the Kyprolis 30 mg Injection, inform your doctor about all your allergic or hypersensitivity reactions to medicines or food. Kyprolis 30 mg Injection can cause fetal harm when administered to a pregnant woman. It is critical not to become pregnant while undergoing therapy and for several months afterwards. Before beginning treatment, discuss effective contraception with your healthcare professional. Inform them immediately if you or your partner becomes pregnant while undergoing therapy. Breastfeeding is usually not advised during this treatment since it is unknown whether this medication passes into breast milk. Do not skip any laboratory checks because Thrombocytopenia, Hepatic Toxicity and Hepatic Failure may occur. If it happens, reduce or interrupt dosing as clinically indicated.
Uses of Kyprolis 30 mg Injection
Medicinal Benefits
Carfilzomib, a proteasome inhibitor, is present in Kyprolis 30 mg Injection. It suppresses proteasomes, preventing protein breakdown in MM (multiple myeloma) cells. When proteasome function is stopped within the MM cell, a protein build-up occurs within the MM cell, which destroys the malignant cells.
Directions for Use
Side Effects of Kyprolis 30 mg Injection
Drug Warnings
Before taking Kyprolis 30 mg Injection, inform your doctor about your medical history and other medications you are currently taking to rule out any potential negative effects. Avoid taking Kyprolis 30 mg Injection if you are pregnant or breastfeeding or allergic to any component present in Kyprolis 30 mg Injection. Both women and men using this Kyprolis 30 mg Injection should use birth control to avoid pregnancy. Inform your doctor right away if you or your partner become pregnant during treatment with Kyprolis 30 mg Injection. Inform your doctor if you have a history of heart failure and ischemia, Pulmonary Hypertension, Thrombocytopenia, low blood pressure or hepatic toxicity; your doctor will closely monitor and manage it. Carfilzomib injection may induce serious or life-threatening responses for up to 24 hours following administration. Before each dose of carfilzomib, you will be given specific drugs to assist in preventing a reaction. If you develop any of the following symptoms after your treatment, contact your doctor right away: fever, chills, joint or muscle pain, flushing or swelling of the face, swelling or tightening of the throat, vomiting, weakness, shortness of breath, disorientation or fainting, or chest tightness or pain.
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
Login/Sign Up
Drug-Diseases Interactions
Login/Sign Up
Drug-Drug Interactions Checker List
Habit Forming
Special Advise
Diet & Lifestyle Advise
Have a query?
Buy best Neoplastic Disorders products by
Intas Pharmaceuticals Ltd
Natco Pharma Ltd
Dr Reddy's Laboratories Ltd
Cipla Ltd
Celon Laboratories Pvt Ltd
Sun Pharmaceutical Industries Ltd
Alkem Laboratories Ltd
United Biotech Pvt Ltd
Zydus Cadila
Zydus Healthcare Ltd
Neon Laboratories Ltd
Glenmark Pharmaceuticals Ltd
Mylan Pharmaceuticals Pvt Ltd
BDR Pharmaceuticals Internationals Pvt Ltd
Emcure Pharmaceuticals Ltd
Adley Formulations
Samarth Life Sciences Pvt Ltd
Hetero Drugs Ltd
Torrent Pharmaceuticals Ltd
Fresenius Kabi India Pvt Ltd
Pfizer Ltd
Admac Lifesciences(Oncology)
Adley Pharmaceuticals Ltd
Novartis India Ltd
Halsted Pharma Pvt Ltd
Getwell Life Sciences India Pvt Ltd
Lupin Ltd
Cadila Healthcare Ltd
Hetero Healthcare Pvt Ltd
GLS Pharma Ltd
Reliance Formulation Pvt Ltd
Abbott India Ltd
Aimcad Biotech Pvt Ltd
Astra Zeneca Pharma India Ltd
Therdose Pharma Pvt Ltd
Axiommax Oncology Pvt Ltd
Biochem Pharmaceutical Industries Ltd
Khandelwal Laboratories Pvt Ltd
Msn Laboratories Pvt Ltd
Aureate Healthcare
Caitlin Oncology
Dabur India Ltd
Zee Laboratories Ltd
Sarabhai Chemicals (India) Pvt Ltd
Wembrace Biopharma Pvt Ltd
Delarc Pharmaceuticals Pvt Ltd
Medaegis Biotek Pvt Ltd
Panacea Biotec Ltd
RPG Life Sciences Ltd
Shilpa Medicare Ltd
Getwell Oncology Pvt Ltd
Ipca Laboratories Ltd
Miracalus Pharma Pvt Ltd
Biocon Ltd
Cadila Pharmaceuticals Ltd
Eli Lilly and Company (India) Pvt Ltd
Ferring Pharmaceuticals Pvt Ltd
Fresenius Kabi Oncology Ltd
Getwell Pharmaceutical Pvt Ltd
Maximal Healthcare Pvt Ltd
Boehringer Ingelheim India Pvt Ltd
Del Trade International Pvt Ltd
Sayre Therapeutics Pvt Ltd
Akumentis Healthcare Ltd
Corona Remedies Pvt Ltd
Eisai Pharmaceuticals India Pvt Ltd
GlaxoSmithKline Pharmaceuticals Ltd
Hilfen Pharmaceuticals Pvt Ltd
Johnson & Johnson Pvt Ltd
Mankind Pharma Pvt Ltd
Merck Ltd
Oncostar Pharma Pvt Ltd
Rhone Poulenc Rorer India Pvt Ltd
Vhb Life Sciences Inc
Zuventus Healthcare Ltd
Admac Pharma Ltd
Adonis Laboratories Pvt Ltd
Alniche Life Sciences Pvt Ltd
BPRL Pvt Ltd
Caitlin Life Care
Dr Care
German Remedies Ltd
Janssen Pharmaceuticals Pvt Ltd
MEDICAMEN BIOTECH LTD
Maxis Healthcare (I) Pvt Ltd
Pharm Products Pvt Ltd
Accord Life Spec Pvt Ltd
Amps Biotech Biotech Pvt Ltd
Aphia Healthcare
Astellas Pharma India Pvt Ltd
Bangalore Pharmaceutical and Research Laboratory Pvt Ltd (BPRL)
Bharat Serums and Vaccines Ltd
Cellgen Biopharma
Cosmic Life Sciences
Daris Biocare
East West Pharma India Pvt Ltd
Hillrock Biotech Pvt Ltd
Lucien Life Sciences
Maneesh Pharmaceuticals Ltd
Medilief Bioscience Pvt Ltd